# Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

> **NCT06345287** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 133 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **RADIATION:** radical radiotherapy (60Gy)
- **RADIATION:** radical radiotherapy (66Gy)
- **RADIATION:** radical radiotherapy (70Gy)
- **COMBINATION_PRODUCT:** anti-PD-1 or PD-L1 antibody

## Key facts

- **NCT ID:** NCT06345287
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2024-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345287, "Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06345287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*